Skip to main content
Search
Search
Search
Search
Main navigation
About pCPA
Who we are
Governance
Strategic plan
Reports
What's new
FAQs
Careers
Negotiations
Browse negotiations
Recent negotiation updates
Brand name drugs
Negotiation process
Expedited negotiation pathways
Generic drugs
Biologics/Biosimilars
pCPA Temporary Access Process (pTAP)
Forms and publications
Contact us
EN
FR
Exjade (deferasirox)
pCPA File Number:
23456
Negotiation Status:
Concluded with an LOI
Indication(s):
Chronic Iron Overload
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
2016-11-02
Negotiation Process Concluded:
2017-04-04